Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP2C9 encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2C9 Antibodies (65) and CYP2C9 Kits (26) and many more products for this protein.
Showing 5 out of 5 products:
Enzyme phenotyping with correlation analysis confirmed the predominant role of CYP2C9 in the biotransformation of siponimod and demonstrated the functional consequence of CYP2C9 genetic polymorphisms and fluconazole on siponimod metabolism.
Comparisons of pharmacokinetics of 25 substrates CYP2C9, CYP2C19, or CYP2D6 in healthy Chinese and European subjects (classified with same enzyme activity) suggest that, for most substrates, limited interethnic pharmacokinetic differences exist (according to the databases used in this study). (CYP2C19 = cytochrome P450 family 2 subfamily C member 19; CYP2D6 = cytochrome P450 family 2 subfamily D member 6)
genetic association studies in population in Scotland: data suggest, in type 2 diabetes treated with sulfonylureas, 2 SNPs in CYP2C9 (CYP2C9*2, R144C, rs1799853; CYP2C9*3, I359L, rs1057910) are associated with drug-induced hypoglycemia; an SNP in POR (POR (show POR Proteins)*28, A503V, rs1057868) is associated with better response to sulfonylureas. (CYP2C9 = cytochrome P450 family 2 subfamily C member 9; POR (show POR Proteins) = cytochrome p450 oxidoreductase (show TXNRD1 Proteins))
The plasma S-warfarin (Cp(S)) time courses following the genotype-based dosing algorithms simulated using the PPK (show GJB2 Proteins) estimates showed African Americans with CYP2C9*1/*1 and any of the VKORC1 (show VKORC1 Proteins) genotypes would have an average Cp(S) at steady state 1.5-1.8 times higher than in Asians and whites.
The final regression models for White and Black patients (Fig. 1) included age, weight, prosthetic valves, amiodarone use, CYP2C9*3, and VKORC1 (show VKORC1 Proteins) 3673 G>A genotypes as covariates, whereas possession of CYP2C9*2 and simvastatin use were retained in the final model for White, but not Black patients.
The present study confirms the variable distribution of CYP2C8 (show CYP2C8 Proteins) (*2 and *3) and CYP2C9 (*2 and *3) allelic polymorphisms among South Indian diabetic populations.
Our results further support a minor contribution of CYP2C9 genetic variability toward steady-state endoxifen concentrations. Integration of clinician and genetic variables into individualized tamoxifen dosing algorithms would marginally improve their accuracy and potentially enhance tamoxifen treatment outcomes.
CYP2C9 genetic variation was associated with long-term overall mortality and non-major bleeding in elderly patients treated with vitamin K antagonists.
Until the age of 19, weight has a far greater effect on Vitamin K antagonist dosing variation than VKORC1 (show VKORC1 Proteins) and CYP2C9 polymorphisms. During the age of 20-40years, VKORC1 (show VKORC1 Proteins) and CYP2C9 polymorphisms play a significant role.
CYP2C9*3 did show significant effect on warfarin dose requirement
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P-450 S-mephenytoin 4-hydroxylase
, cytochrome P-450MP
, cytochrome P450 2C9
, cytochrome P450 PB-1
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase